- Conditions
- Hepatitis C
- Interventions
- Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 395 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 22
- States / cities
- Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–32
of 32
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis B
- Interventions
- JNJ-73763989, JNJ-56136379, Entecavir (ETV), Tenofovir disoproxil, Tenofovir alafenamide (TAF), PegIFN-alpha-2a (Optional)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis C Virus (HCV)
- Interventions
- Glecaprevir/Pibrentasvir
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- San Diego, California • San Francisco, California • West Hollywood, California + 2 more
- Conditions
- Hepatitis C
- Interventions
- BI 201335, PegIFN/RBV
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • North Little Rock, Arkansas • Los Angeles, California + 16 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Debio 025, Peg-IFNα2a, Ribavirin
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 7
- States / cities
- La Jolla, California • Gainesville, Florida • Miami, Florida + 4 more
- Conditions
- Hepatitis C
- Interventions
- LADR Treatment
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 678 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 18
- States / cities
- North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more
- Conditions
- Hepatitis C
- Interventions
- TMC435, Placebo, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV)
- Drug
- Lead sponsor
- Janssen R&D Ireland
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 11
- States / cities
- Bakersfield, California • Aurora, Colorado • Jacksonville, Florida + 8 more